% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • left2rightdoor left2rightdoor Nov 26, 2012 3:06 PM Flag

    The Results Are Not In.

    Finn, Markovic, Joseph Therapies for Metastatic Melanoma, Past Present and Future

    With approximately 13,000 annual deaths and a median overall survival (OS) of 8 to 18 months, metastatic melanoma is the most aggressive form of skin cancer [1]. Until 2011, only two FDA therapies for metastatic melanoma were approved, dacarbazine and high dose interleukin 2 (HD IL-2), both of which do not increase median OS [2-4]. Dacarbazine is limited by a low response rate (10% to 15%) and an overall survival of eight months [2]. HD IL-2 is limited by an even lower response rate (6% to 10%) and severe toxicity with only a minority of patients achieving a long-term, durable response [3,4].

0.430.00(-0.69%)2:44 PMEDT